Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Aptose Biosciences, Inc. announced the dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase Ia/b clinical trial in patients with relapsed or refractory acute myeloid leukemia.